The initial wave of Generative AI excitement in the life sciences is meeting a sobering reality: the “Implementation Gauntlet.” While the potential for AI to revolutionize the DMTA cycle is undisputed, many organizations remain trapped in “Pilot Purgatory,” unable to scale individual successes into enterprise-wide impact. Our latest whitepaper, “From Hype to Implementation,” deconstructs this […]
From Hype To Implementation Read More »
As a boy growing up in a village on the outskirts of Vienna, this time of year always held a certain amount of excitement and trepidation for me. Every year on the evening of December 5th, after a feverish amount of shoe polishing, and sweeping of the front porch we would await the arrival of
Beyond JPM 2025: Streamlining Biotech Project & Portfolio Management Read More »
2024 has been a year of exciting advancements at Aspen Biosciences, marked by the expansion of our Pipeline and PharmExchange platforms and the launch of innovative features designed to empower drug discovery efforts and to improve their capital efficiency. We’re thrilled to share some of the highlights: New Modules: New Features: Overall, these new modules
2024: Year In Review Read More »
Lessons Learned Creating a new drug discovery software platform is a complex process. We’ve spent the last 15 years creating new and innovative tools for drug discovery companies – everything from custom reagent management systems, to kinase profiling tools, automated chemistry, protein production and DEL-based drug discovery platforms. In addition to managing the day-to-day aspects
One of the key lessons learned from all of the implementations that we’ve done is a need for flexibility. A customer might tell us that they need X, but it often evolves into Y over the course of the project. Creating a system that is evolvable has its own unique challenges: Over the years
Metadata-Driven Collaboration in Biotech and Pharma: Pipeline – Origins Stories, Pt 2 Read More »
Over the past 5 years, AI and ML have advanced significantly in the pharmaceutical industry. We explored Generative AI, like ChatGPT, for mining drug development pipeline information. Our whitepaper documents the state-of-the-art and assesses AI’s readiness for such tasks, using Foghorn Therapeutics as a case study.
Generative AI : ChatGPT Experiments Read More »
This year saw a return to major industry events. Highlights included attending BioPharma PM, BioIT World, and BIO conferences and showcasing our Pipeline Program Management software. We launched a successful “Roadmap Informatics & Laboratory Planning Service” and completed significant client projects, including Diagnostics LIMS System, DEL Library Design & Screening, and Automated Synthesis modules.
Year in Review | Aspen Biosciences Read More »
As the country reopens, biotech companies navigate the new normal. They seek solutions for essential on-site personnel, productivity, and safe collaboration. Common strategies include hybrid work models, improved lab protocols, and increased use of virtual tools. Continuous evaluation ensures safety and efficiency.
Biotech Companies Adapting to COVID-19 Challenges: Strategies and Solutions Read More »
In a couple of recent posts I wrote about the current landscape of life science podcasts, and highlighted some of the consistently highest rated ones, and some of the podcasts that deserve a second look. One thing has become readily apparent though, is that even with the variety of podcasts currently available, there are a
Missed Opportunities in Life Science Podcasts Read More »
Some interesting new features in Cytoscape, the open source biological network analysis application.
Tinkering with the Latest Cytoscape Release Read More »
